Gavin Hirst serves as senior vice president, Chemistry, and interim chief scientific officer for Turning Point Therapeutics. Dr. Hirst has over 30 years of pharmaceutical and biotech experience developing more than 10 clinical-stage drug candidates spanning five therapeutic areas and is coinventor of the approved drug Vaborbactam®, a potent inhibitor of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC) for use in combination with meropenem for treatment of complicated urinary tract infections.
Prior to joining Turning Point Therapeutics in 2020, Dr. Hirst was global head of Integrated Drug Discovery (DiscoveryOneTM) at Eurofins Discovery where he led a global multi-disciplined team that provided fully integrated small-molecule drug discovery services to global clients.
Preceding Eurofins, Dr. Hirst was senior director and head of Immunology Chemistry at the Janssen Pharmaceutical Company where he was responsible for a broad portfolio of small-molecule assets, including lorpucitinib, a clinical stage GI-restricted pan-JAK inhibitor for the treatment of Familial adenomatous polyposis, a form of colorectal cancer. Previously he was vice president of Research at Takeda California and was accountable for the strategic direction, portfolio prioritization, and management of research across cancer, metabolic diseases and immunology; senior director and head of Medicinal Chemistry at SGX Pharmaceuticals and associate director of Medicinal Chemistry at Abbott Laboratories (now Abbvie).
Dr. Hirst completed his post-doctoral training in Organic Chemistry at the University of California, Irvine and his Ph.D. in Chemistry at the University of Southampton in the UK.